Glymphatic System Dysfunction in Central Nervous System Diseases and Mood Disorders

Dianjun Zhang1,2,3, Xinyu Li1,2,3 and Baoman Li1,2,3*

1 Department of Forensic Analytical Toxicology, School of Forensic Medicine, China Medical University, Shenyang, China, 2 Liaoning Province Key Laboratory of Forensic Bio-evidence Sciences, School of Forensic Medicine, China Medical University, Shenyang, China, 3 China Medical University Center of Forensic Investigation, School of Forensic Medicine, China Medical University, Shenyang, China

The glymphatic system, a recently discovered macroscopic waste removal system in the brain, has many unknown aspects, especially its driving forces and relationship with sleep, and thus further explorations of the relationship between the glymphatic system and a variety of possible related diseases are urgently needed. Here, we focus on the progress in current research on the role of the glymphatic system in several common central nervous system diseases and mood disorders, discuss the structural and functional abnormalities of the glymphatic system which may occur before or during the pathophysiological progress and the possible underlying mechanisms. We emphasize the relationship between sleep and the glymphatic system under pathological conditions and summarize the common imaging techniques for the glymphatic system currently available. The perfection of the glymphatic system hypothesis and the exploration of the effects of aging and endocrine factors on the central and peripheral regulatory pathways through the glymphatic system still require exploration in the future.

Keywords: glymphatic system, mood disorder, astrocyte, sleep, central nervous system disease

INTRODUCTION

The “glymphatic system” (glial-lymphatic system), which was proposed by Jeffrey Iliff, Maiken Nedergaard and her team in 2012, mainly refers to a macroscopic waste clearance system similar to the peripheral lymphoid system in the brain (Iliff et al., 2012). Numerous studies have shown that the glymphatic system exerts a significant effect on the distribution of a variety of substances in the brain, including not only its core waste clearance function but also the distribution and transport of nutrients such as glucose (Lundgaard et al., 2015), some possible treatment substances (recombinant adeno-associated viral vectors) (Murlidharan et al., 2016) and glial calcium signaling (Rangroo Thrane et al., 2013). Because of its important physiological role, the glymphatic system is considered related to the occurrence and development of a variety of diseases (Rasmussen et al., 2018), including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, as well as mood disorders (Yan et al., 2021).

The brain contains a very rich and complex network of blood vessels. Most of the blood vessels in the brain parenchyma are wrapped by the protruding processes (endfeet) of astrocytes (Nagelhus and Ottersen, 2013; Korogod et al., 2015). The perivascular space (PVS) between the astrocytic endfeet and the vascular wall is filled with cerebrospinal fluid (CSF), which is the main site of
action of the glymphatic system. The water channel aquaporin-4 (AQP4) occupies approximately 50% of the surface area of astrocyte processes located close to or in direct contact with blood vessels (Nielsen et al., 1997). CSF passing through the subarachnoid space enters the stroma through AQP4 located in the space around the artery, pushes the interstitial fluid (ISF) to carry solute to the perivascular space, and then flows out of the brain into the cervical lymphatic system (Murtha et al., 2014). Relying on the PVS, astrocytes are the core, and the AQP4-dependent material transport system is the glymphatic system.

The main factors influencing the glymphatic system include AQP4, sleep and arterial pulsation (Jessen et al., 2015). However, the role of arterial pulsation in it is still open to question. AQP4 is a small hydrophobic intrinsic plasma membrane protein, and its physiological function is to promote the transport of water through the plasma membrane. Because its expression on astrocytes is highly polarized (mainly concentrated on the capillary surface of the endfeet) (Nielsen et al., 1997), it reduces the resistance of CSF transport between the PVS and interstitial space (Iliff et al., 2012). Therefore, astrocytes have the ability to guide the transformation of CSF and ISF into each other in both the space around the arteries and veins.

Some studies have shown that the glymphatic system is inhibited in the awake state but enhanced in the sleep state (Xie et al., 2013). Sleep may affect the glymphatic system by changing the volume of the brain stroma. The brain interstitial volume fraction in asleep and anesthetized mice was higher than that in the awake state, which reduced the resistance of CSF flowing into the brain stroma and was beneficial to the operation of the glymphatic system (Xie et al., 2013). In addition, norepinephrine is a major neurotransmitter involved in the awakening state (Berridge and Waterhouse, 2003), and a sudden increase in its levels during awakening increases the cell volume in the brain parenchyma and may resist the inflow of CSF by reducing the interstitial volume (O’Donnell et al., 2012). Although controversy persists regarding whether the choroid plexus is the source of CSF production (Oresković and Klarica, 2010; Trillo-Contreras et al., 2019), several studies have confirmed that norepinephrine directly acts on choroid plexus epithelial cells to inhibit CSF production (Nilsson et al., 1992), which may be part of the mechanism of the sleep inhibitory glymphatic system.

Generally, intracranial arterial pulsation is presumed to be the main physical force promoting the operation of the glymphatic system (Jessen et al., 2015). Related experiments have indicated that the efficiency of CSF flowing into the brain is positively correlated with the pulsation of arteries (cortical penetrating arteries) (Iliff et al., 2013b). Every 10-beat reduction in heart rate reduces waste clearance and leads to an approximately 20% increase in β-amyloid protein (Aβ) levels in the brain parenchyma, while an increase in heart rate of 30 beats per minute produced an approximately 30% decrease in Aβ levels in the brain parenchyma (Kyrtos and Baras, 2015). Although the glymphatic system is most active during sleep (Xie et al., 2013), blood pressure, cerebral blood flow (Kotajima et al., 2005) and vascular movement (Zhang and Khatami, 2014) are all at a low level, which contradicts this conclusion. However, a study by Goulay et al. (2018) in non-human primates confirmed that solute clearance in the brain is severely impaired in the presence of CSF leakage, supporting a link between CSF circulation and glymphatic system. Therefore, the relationship between arterial pulsation and the glymphatic system is not fully understood.

This review summarizes and introduces the research progress on understanding the role of the glymphatic system in central nervous system diseases and mood disorders, discusses the possible mechanisms underlying the occurrence and development of related diseases. We focus on the abnormalities in various components of the glymphatic system and the role of sleep in the development of the disease, combined with summarizing the commonly used visual imaging methods, to provide strategies for the prevention and treatment of related diseases in the future.

CENTRAL NERVOUS SYSTEM DISEASES

Neurodegenerative Diseases

Neurodegenerative diseases (NDDs) are diseases characterized by progressive dysfunction and neuronal loss (Kovacs, 2016). Common NDDs include Alzheimer’s disease (AD), Parkinson’s disease (PD), atrophypathic lateral sclerosis (ALS) and Huntington's disease (HD). A possible cause of these destructive diseases is the abnormal aggregation and deposition of toxic proteins such as Aβ, α-synuclein, TAR-DNA-binding protein 43 and mutant huntingtin protein respectively (Kovacs, 2016; Ruz et al., 2020). This pathological deposition occurs not only in the brain but also in peripheral organs (Kovacs, 2019) and affects neurons and glial cells simultaneously (Kovacs, 2016).

Alzheimer’s Disease

Alzheimer’s disease is a relatively slowly progressing neurodegenerative disease. As a common type of dementia, its main pathological features are the deposition of senile plaques and neurofibrillary tangles (NFTs) (De-Paula et al., 2012; Tarasoff-Conway et al., 2015). Senile plaques (also known as neuritic plaques) are attributed to the extracellular deposition of Aβ, and the accumulation of high-density plaques in the hippocampus, amygdala and cerebral cortex leads to the activation of astrocytes and microglia, synaptic loss, and cognitive impairment (Tabaton and Piccini, 2005; Armstrong, 2009; Chen et al., 2017). Aβ deposition also ossifies blood vessels and reduces arterial pulsation, leading to cerebral amyloid angiopathy (CAA) (Serrano-Pozo et al., 2011). Tau is a splice variant of microtubule-associated protein tau (MAPT), which is an intracellular neuronal protein that stabilizes axons (Shea and Beermann, 1994). In patients with AD, intracellular tau (i-tau) is hyperphosphorylated, resulting in the formation of insoluble neurofibrillary tangles that are difficult to remove (Binder et al., 2005).

Schubert et al. (2019) uses MRI and dynamic 11C-PiB PET to prove that CSF clearance deficits in AD associated with Aβ deposits. A study using ultrafast 10 Hz magnetic resonance encephalography also showed that pervasive abnormality in (peri) vascular cerebrospinal fluid impulse propagation exists in patients with AD, which can damage glymphatic brain clearance.
of Aβ in AD (Rajna et al., 2021). The glymphatic system is inhibited in an AD (APP/PS1) mouse model, and this inhibition occurs with or without showing extensive Aβ deposits, due to the accumulation of toxic Aβ species, such as soluble oligomers (Peng et al., 2016), this indicates that there may be a complex interaction relationship between AD and glymphatic system. Using transgenic mice, Patel et al. (2019) confirmed that the glymphatic system plays an important role in the transport and clearance of extracellular tau protein. As the functional core of the glymphatic system, AQP4 promotes the clearance of the interstitial aggregation of proteins, including Aβ and tau (Mader and Brimberg, 2019). Two-photon imaging studies showed that the Aβ clearance rate of AQP4 knockout mice is decreased by 55–65% (Iliff et al., 2012), indicating that AQP4 plays an important role in the clearance of extracellular Aβ (EAβ) in mice. The pharmacological inhibition of AQP4 (AQP4 inhibitor TGN-020) also significantly reduces the tau clearance rate (Harrison et al., 2020). Using human transcriptomic data, researchers demonstrated that the expression of perivascular astroglial gene products are associated with phosphorylated tau levels in temporal cortex (Simon et al., 2018). However, under the pathological condition of AD, AQP4 may be abnormal. The lower concentrations of Aβ(1–42) (a soluble monomeric isomer of Aβ; Zheng et al., 2012) increased AQP4 expression in cultured mouse cortical astrocytes, while the higher concentrations of Aβ(1–42) decreased AQP4 expression (Yang et al., 2012). AQP4 depolarization was observed in the brains of patients with AD (Zeppelinfeld et al., 2017) and AD model mice (Xu et al., 2015). These deletions or changes in the location of polarization substantially inhibit the clearance function of the glymphatic system, resulting in the accumulation of large amounts of Aβ and tau in the brain, leading to the continuous deterioration of AD.

One of the characteristics of patients with AD is sleep disturbance (Moran et al., 2005). Sleep-wake cycle disorders caused by Aβ accumulation and loss of diurnal fluctuations in Aβ levels in ISF are observed in mice and humans (Roh et al., 2012), while the glymphatic system is most active during sleep. The Aβ clearance rate in the brain of sleeping mice is twice as fast as that of awake mice (Xie et al., 2013), and Aβ deposition in the human brain increases significantly after sleep deprivation for one night (Shokri-Kojori et al., 2018). Based on these results, sleep plays an important role in Aβ clearance. Another study showed that people with poor sleep habits and specific genetic variations in AQP4 have more Aβ deposits in the brain (Rainey-Smith et al., 2018), suggesting that AD may inhibit glymphatic system function through both AQP4 abnormalities and sleep disorders, resulting in protein accumulation and related pathological changes.

Parkinson's Disease

Parkinson's disease is a common neurodegenerative disease, and its symptoms mainly include motor disorders (neuromuscular stiffness, motor retardation, and tremor) and non-motor disorders (sleep disorders, constipation, and malnutrition) (Henderson et al., 2019). The main pathological feature of PD is the loss of dopaminergic neurons in the substantia nigra, accompanied by the accumulation of α-synuclein (α-syn) in Lewy bodies (Bohnen and Hu, 2019). Blocking meningeal lymphatic drainage by ligating the deep cervical lymph nodes in mice has also been shown to aggravate the pathological and motor symptoms caused by α-syn (Zou et al., 2019), indicating a possible relationship between the glymphatic system and PD.

α-Syn is considered a protein that regulates synaptic neurotransmitter release and autophagy (Bobela et al., 2015), and its deposition in the brain is the basis of the neuropathology of PD. α-Syn accumulates in many parts of the brain, causing neuroinflammation. The interaction between neuroinflammation and systemic oxidative stress may exacerbate reactive astrogliosis and potential damage to the glymphatic system (Verkhratsky et al., 2015; Chiang et al., 2018), while the neurotoxicity of α-syn itself promotes the loss of dopaminergic neurons in the substantia nigra-striatum circuit, leading to related symptoms (Taylor et al., 2002; Kovacs et al., 2008). Some experiments have shown a negative correlation between α-syn deposition and AQP4 expression (Hoshi et al., 2017), while a decrease in AQP4 expression aggravates the degeneration of dopaminergic neurons (Zhang et al., 2016). To some extent, this finding explains the possible pathological relationship between the glymphatic system and PD.

Sleep disorders and poor sleep quality are strongly associated with decreased cognitive performance in patients with PD (Stavitsky et al., 2012; Bohnen and Hu, 2019). One of the common symptoms is rapid eye movement-sleep behavior disorder (RBD), a sleep disorder characterized by a lack of muscle tone, which leads to abnormal body movement during REM sleep and often occurs before motor symptoms (Barber and Dashtipour, 2012). A study of autopsy samples showed a cumulative increase in α-syn levels in many regions of the brains of patients with PD presenting sleep disorders (Kalaitzakis et al., 2013), and evidence that sleep dysfunction in patients with PD is caused by the degeneration of dopaminergic neurons in a pathway similar to RBD has been reported (Dickson et al., 2009; Kalaitzakis and Pearce, 2009; Grinberg et al., 2010). Dopamine, similar to norepinephrine, increases alertness and promotes arousal, and its levels increase mainly in the state of awakening (Isaac and Berridge, 2003; Murillo-Rodríguez et al., 2009). There is a possible interaction between dopamine and clock gene expression, and dopaminergic dysfunction may lead to circadian rhythm disorder (Imbesi et al., 2009; Albrecht, 2013). In addition, some experiments have shown that dopamine reduces the expression of AQP4 in striatal astrocytes, and this downregulation causes the dopamine-induced decrease in proliferation of these cells (Küppers et al., 2008). Based on a large number of experimental results, researchers speculated a vicious cycle, which is the combined neurotoxic effects of α-syn and dopaminergic neurons lead to glymphatic system dysfunction by causing REM sleep abnormalities, circadian rhythm and clock gene dysfunction, while the decrease of α-syn clearance furthers the PD degenerative process (Sundaram et al., 2019).

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease characterized by the death of supraspinal and supraspinal neurons responsible for controlling...
various muscles (Kiernan et al., 2011). Many proteins are related to ALS, such as superoxide dismutase 1 (SOD1), fusion sarcoma (FUS) and Aaxin-2, among which TAR-DNA-binding protein 43 (TDP-43) is the most relevant; it binds RNA and regulates mRNAs involved in neuronal development (Geuens et al., 2016; Prasad et al., 2019). TDP-43 inclusion bodies are widely regarded as pathological markers of ALS, and more than 95% of patients with ALS show TDP-43 deposition (Neumann et al., 2006). TDP-43 deposition represents a possible glymphatic disorder, and the observation of AQP4 overexpression (Nicaise et al., 2009; Dai et al., 2017) and depolarization (Dai et al., 2017) in mouse or rat ALS models supports this speculation. AQP4 depolarization is consistent with the progression of ALS, and its persistence will interfere with neuronal function (Dai et al., 2017). A recent study observed that the cervical spinal cord clearance of the fluorescent dye-labeled tracer (ovalbumin) injected through the cisterna magna of ALS model SOD1G93A mice decreased by approximately 35% compared with wild-type mice, suggesting that ALS model mice have a dysfunctional glymphatic system (Hirose et al., 2021). Meng et al. (2019) temporarily increase the permeability of the blood-brain barrier, recording gadobutrol patterns in the PVS, subarachnoid space, and space surrounding large cortical draining veins in ALS patients, suggesting glymphatic efflux persists in humans. Another pathological feature of ALS is reactive glial hyperplasia characterized by astrocyte hypertrophy and microglial proliferation (Ng et al., 2015), which may also indicate potential glymphatic system damage.

In addition, sleep quality and respiratory function are negatively correlated with the severity of ALS (Ahmed et al., 2016). Increased norepinephrine concentrations have been detected in the CSF, plasma and spinal cord tissues (thoracic and lumbar spinal cord) of patients with ALS (Bertel et al., 1991), which may also affect the glymphatic system.

**Traumatic Brain Injury**

Traumatic brain injury (TBI) increases the risk of other neurological and mental disorders, including chronic traumatic encephalopathy, AD, anxiety, depression and personality disorders (Bolte and Lukens, 2021). TBI induces the release of Aβ and C-tau. C-tau is a biomarker of brain injury, and its release is related to the severity of TBI (Gabbita et al., 2005). Several methods (AQP4 gene knockout, cisterna magna cisternostomy, acetazolamide treatment, and sleep deprivation) have been used to inhibit the function of the glymphatic system in the mouse brain. The plasma levels of three biomarkers of TBI [S100β, glial fibrillary acidic protein (GFAP) and neuron-specific enolase] have been decreased, indicating that these biomarkers leave the brain through the glymphatic system (Plog et al., 2015), while this glymphatic system-dependent process slows down after TBI (Iliff et al., 2014). In patients with TBI, astroglial inflammation, C-tau, p-tau and Aβ protein waste accumulation and other pathological manifestations are considered to lead to glymphatic system dysfunction (Jessen et al., 2015), and subarachnoid hemorrhage caused by head trauma is also considered to damage the glymphatic system (Gaberel et al., 2014). Inglese et al. (2005) used MRI to evaluate the structural abnormalities of the brain of 24 patients with mild TBI, compared with healthy control subjects, the number of dilated Virchow-Robin spaces (VRS) in the brain of patients with mild TBI increased, indicating the potential dysfunction of glymphatic system. Experiments have suggested that TBI can lead to the clearance of radioactive tracers from the mouse brain: the function of the glymphatic system is reduced by approximately 60% and lasts for at least 28 days (Iliff et al., 2014). This dysfunction of the glymphatic system is related to the depolarization of AQP4 (Ren et al., 2013; Mestre et al., 2018) and has a certain regional specificity (Christensen et al., 2020). As the severity of TBI increases, the recovery time of the AQP4 polarization distribution is correspondingly prolonged (no recovery is observed after 28 days) (Ren et al., 2013). TBI is also related to the formation of astrocyte scars and the continuous activation of neuroinflammation (Iliff et al., 2014). Inflammation and proliferation of reactive astrocytes and microglia appear around the injured site (Giza and Hovda, 2014), while the polarization of AQP4 on the astrocyte endfeet seems to be closely related to the proliferation of reactive astrocytes.

In addition, sleep disorder is one of the common complaints in patients with head trauma. Somnolence, insomnia, and other symptoms appear in a large number of patients with TBI (Clinchot et al., 1998; Ouellet et al., 2006; Verma et al., 2007; Collen et al., 2012), suggesting that TBI damages the function of the glymphatic system by affecting patients’ normal sleep and subsequently resulting in a large accumulation of related biomarkers in the brain.

**Stroke**

Stroke is a group of diseases that cause brain damage due to the sudden rupture of cerebral blood vessels or vascular obstruction, including ischemic stroke and hemorrhagic stroke. In mice, both ischemic stroke and hemorrhagic stroke have been shown to lead to the blockage of CSF circulation and damage to the glymphatic pathway (Iliff et al., 2014). Goulay et al. (2017) reported a similar phenomenon in non-human primates: after subarachnoid hemorrhage (SAH), the deposition of fibrin and fibrinogen in the PVS leads to glymphatic system dysfunction and finally the deterioration of cerebral ischemia and brain edema; the application of tissue-type plasminogen activator to remove the deposits in the PVS alleviates the pathological symptoms of SAH. Liu et al. (2021) used routine MRI, diffusion tensor images scan of the brain and other methods to measure the ALPS-index and other indexes of patients with carotid plaque, which confirmed that there may be impairment of glymphatic system in patients with carotid plaque.

Post-SAH glymphatic system dysfunction significantly reduces the amount of CSF flowing into and out of the brain (Liu E. et al., 2020) and causes pathological manifestations such as vasculitis and neuroinflammation (Luo et al., 2016). The main mechanism may be the destruction of the blood brain barrier after stroke (Yang and Rosenberg, 2011). Aβ infiltrates into the CSF and brain parenchyma (Scheuner et al., 1996) and accumulates transiently in the brain parenchyma and blood vessel walls (Garcia-Alloza et al., 2011; Okamoto et al., 2012), leading to inflammation. A study has shown significantly increased AQP4 expression in the artery after SAH.
but no significant change in AQP4 expression was detected in the vein, which may indicate a significant increase in the inflow of CSF from the periartrial space, while the volume of ISF expands due to the constant expression of AQP4 in the vein to eventually lead to the deterioration of brain edema (Liu E. et al., 2020). Researchers have observed increased AQP4 expression during the response to hypoxia: acute hypoxia induces AQP4 localization in cortical astrocytes and increases water permeability (Kitchen et al., 2020). This result confirms the findings reported by Mestre et al. (2020) that the entry of CSF into the brain through the glymphatic pathway is the main mechanism of edema formation and ion disturbance in the early stage of ischemic stroke. Other researchers have found that the function of the glymphatic system changes over time after ischemic stroke, and CSF inflow increases a few minutes after stroke but remains relatively slow in the following period (until 7 days) (Lin et al., 2020). Moreover, local destruction of the glymphatic system was detected around the infarct area, while the extracellular fluid in the infarct area was still toxic to neurons 7 weeks after stroke, causing long-term damage because it was not cleared in a timely manner (Zbesko et al., 2018).

Cerebral apoplexy-induced damage to the function of the glymphatic system may also lead to accelerated deposition of Aβ, tau and other proteins, which in turn trigger neurodegenerative diseases such as AD, dementia, and cognitive impairment.

Idiopathic Normal Pressure Hydrocephalus
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological disease characterized by Hakeem’s triad (dementia, gait disorder, and urinary incontinence) (Lu et al., 2020). Its typical imaging findings are ventricular enlargement, wide lateral fissure, and subarachnoid stenosis (Capone et al., 2020), but intracranial pressure usually remains normal (Hakim and Adams, 1965). INPH is considered one of the most common causes of dementia and one of the risk factors for the subsequent development of AD (Ringstad et al., 2017). Different studies have used enhanced MRI to observe delayed clearance of the intrathecal CSF tracer gadobutrol in patients with iNPH (Ringstad et al., 2017; Eide and Ringstad, 2019). Yokota et al. (2019) performed diffusion tensor imaging (DTI) along the perivascular space (ALPS) and observed lower diffusivity ALPS in patients with iNPH than in the control group. Other groups reported delayed enrichment and clearance of tracers in the visual pathway of patients with iNPH (Jacobsen et al., 2020).

Glymphatic system dysfunction is a component of the pathological process of iNPH. Many possible mechanisms of glymphatic system dysfunction in iNPH pathology have been proposed. One is that excess CSF will be trapped in the dilated PVS and oppress the penetrating artery in the parenchyma of the brain to reduce its pulsation (Gallina et al., 2020). As a possible driving force of the glymphatic system, the inhibition of arterial pulsation may reduce the function of the glymphatic system. Second, decreased AQP4 expression in astrocytes of patients with iNPH mainly results in a decrease in the density of the endfeet around the blood vessels (depolarization) (Eide and Hansson, 2018; Reeves et al., 2020). As a disease related to aging, the prevalence rate of iNPH increases exponentially with age (Martín-Láez et al., 2016). The progressive depolarization of AQP4 caused by aging will further inhibit the operation of the glymphatic system (Hasan-Olive et al., 2019). Finally, patients with iNPH are often diagnosed with sleep disorders (Román et al., 2019). Obstructive sleep apnea (OSA) is a common sleep disorder associated with AD (Ooms and Ju, 2016), affecting 90.3% of patients with iNPH in one study (Román et al., 2019). Abnormal respiratory movement (intermittent airway obstruction) in people with OSA may increase intracranial venous pressure by increasing intrathoracic negative pressure and reducing venous reflux, periventricular CSF outflow and CSF-ISF exchange (Román et al., 2019), and may damage the glymphatic system while promoting the development of iNPH.

SLEEP AND MENTAL DISORDERS
According to recent studies, mood disorders are also associated with the glymphatic system (Xia et al., 2017b; Liu X. et al., 2020). Mood disorders are a group of mental disorders characterized by emotional imbalance, including major depressive disorder (MDD) and bipolar disorder (BD). In addition to emotional abnormalities, sleep abnormalities are also strongly associated with symptoms associated with mood disorders (Jackson et al., 2003; Lyall et al., 2018). Sleep disorder is a common complaint of patients with mood disorders, while paradoxical sleep deprivation (PSD) causes manic-like behavior in mice (Arent et al., 2015), induces mania in healthy subjects, and exacerbates manic episodes or lead to the transition from depression to mania in patients with bipolar disorder (Kaplan and Harvey, 2013). In addition, some antidepressant drugs, such as ketamine, exert an effect on sleep patterns (Duncan et al., 2017). The aforementioned evidence proves that sleep disorders play an important role in the occurrence and development of mood disorders, and because of the close relationship between sleep and the glymphatic system, we speculate that glymphatic system dysfunction is one of the possible pathological mechanisms of mood disorders. Due to altered sleep patterns or quality, glymphatic system function is abnormal, which leads to or aggravates mood disorders.

Sleep Disorder
The relationship between sleep and the glymphatic system is inseparable. During non-rapid eye movement (NREM) sleep, a consistent pattern of slow wave activity and CSF inflow is observed, supporting the exciting possibility that sleep regulates glymphatic function (Fultz et al., 2019). Siow et al. (2021) used diffusion tensor imaging-analysis along the perivascular space (DTI-ALPS) index as the MRI marker of glymphatic function, identified significant associations between glymphatic function and sleep in 84 elderly participants. However, the specific interaction between the glymphatic system and sleep remains unclear. Circadian rhythm is a natural internal process that regulates the sleep/wake cycle and repeats roughly every 24 h. Sleep/wake cycle refers to a physiological state that occurs
alternately between sleep and awakening. Although previous experiments have shown that the glymphatic system clearance function is related to animal sleep/awakening states (Xie et al., 2013), recent experiments have shown that the glymphatic system is regulated by circadian rhythm rather than the sleep/wake cycle (Cai et al., 2020; Hablitz et al., 2020), which means that the glymphatic system may also be affected by endogenous hormones, not just by sleep/awakening state. The redistribution of intraventricular contrast agent in conscious rats was the lowest in the light stage and the highest in the dark phase in both normal and reverse light-dark cycles, which proved the possible effect of alternating day and night cycles on the clearance function of the glymphatic system (Cai et al., 2020). The clearance function of the glymphatic system peaks at the most likely time mice sleep (noon) during the day, and the diurnal difference in glymphatic system function persists under constant light conditions, suggesting that this diurnal difference arises from endogenous regulation (Hablitz et al., 2020). At the same time, the distribution of polarized AQP4 on the endfeet of astrocytes is also related to different periods of the same day, and deletion of the AQP4 gene effectively eliminates the diurnal regulation of the CSF distribution (Hablitz et al., 2020).

Regardless of whether the glymphatic system is regulated by circadian rhythm, the sleep/wake cycle or both, circadian rhythms and sleep/wake cycles in patients with mood disorders have both been shown to be affected to varying degrees (Kalmbach et al., 2015; Bradley et al., 2017; Park et al., 2018). Symptoms of depression show diurnal patterns that are worse in the morning or at night (Rustung and Larsen, 1998), while genomic studies have further discovered the relationship between circadian rhythms and mood disorders. The circadian rhythm gene CRY2 has been proven to be related to the rapid cycling of BD (Sjöholm et al., 2010). The abnormal expression of circadian rhythm genes such as BMAL1, PER1-3, REV-ERBA, DBP, and BHLHE40/41 was also observed in the postmortem brain tissues of patients with MDD (Li et al., 2013). Sufficient studies on the sleep/wake cycle have proven the relationship between mood disorders and this cycle. As shown in our previous study, fluoxetine, a specific serotonin reuptake inhibitor widely used in the clinic, increases the activity of signal transducer and activator of transcription-3 (STAT3) in astrocytes, reverses the changes in the expression and function of nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasomes stimulated by sleep deprivation, and then inhibits SD-induced neuroinflammation and neuronal apoptosis (Xia et al., 2017a). Sleep disorders in patients with mood disorders are likely to affect the function of the glymphatic system, but the significance of this alteration in the occurrence and development of mood disorders remains unclear.

Mood Disorders

We observed that AQP4 expression was downregulated in the cortex and hippocampus of a mouse model of chronic unpredictable mild stress (CUMS), the widespread loss distribution of AQP4 on astrocytes suggesting a disorder in the glymphatic system, and an increase in Aβ deposition was detected (Xia et al., 2017b). In addition, this disorder was improved by fluoxetine and polyunsaturated fatty acids (PUFAs) (Xia et al., 2017b; Liu X. et al., 2020). Our previous experimental results have shown that iron dextran damages the glymphatic system in the frontal cortex by increasing reactive astrogliosis, which was indicated by an increase in glial fibrillary acidic protein expression, inducing neuronal apoptosis and therefore aggravates depression-like behavior caused by CUMS (Liang et al., 2020). Decreases in the number of astrocytes and AQP4 expression were observed in other animal models of depression, such as chronic mild stress (CMS) (Gong et al., 2012) and chronic psychosocial stress (Czéh et al., 2006). Reactive astrocyte proliferation and changes in AQP4 expression are common in postmortem tissues from patients with depression, but the related experiments have produced contradictory results. Glial fibrillary acidic protein (GFAP) is one of the specific biomarkers of astrocytes. Several experimental results show that depression reduces its expression in different regions of the brain (Altshuler et al., 2010; Bernard et al., 2011; Gittins and Harrison, 2011; Cobb et al., 2016; Torres-Platas et al., 2016), but some experiments show that its expression increases (Barley et al., 2009) or it not significantly changed (Williams et al., 2013; Table 1). The expression of AQP4 in the brains of patients with MDD was shown to be downregulated by different groups [locus coeruleus (Bernard et al., 2011), hippocampus (Medina et al., 2016)]. However, in an oligonucleotide microarray analysis and qPCR study of postmortem brain tissues from patients with mood disorder, the expression of the AQP4 gene U34646 was upregulated in the prefrontal cortex (Iwamoto et al., 2004).

Similar to depression, astrocyte dysfunction is a very common characteristic of the occurrence and development of BD, but several experimental results show different trends. The density of astrocytes in the frontal cortex (Hercher et al., 2014), cingulate cortex (Williams et al., 2013), amygdala (Altshuler et al., 2010; Puntazopoulos et al., 2010), and entorhinal cortex (Puntazopoulos et al., 2010) did not change after death. However, some researchers have reached different conclusions: GFAP-positive astrocytes showed a decreasing trend in the BA10 (Johnston-Wilson et al., 2000) and BA11/47 (Toro et al., 2006) regions of the brain; and GFAP mRNA (Webster et al., 2005) or protein (Fatemi et al., 2004) expression decreased (see Table 1). Central nervous system-specific protein (S100β) is a calcium-binding protein that is mainly produced and secreted by astrocytes in the central nervous system. S100β is a commonly used astrocyte marker, and its level is increased in BA40 but decreased in BA9 (Dean et al., 2006). In a meta-analysis of serum S100β levels, serum levels of S100β were increased in patients with BD during the manic state (da Rosa et al., 2016).

Based on these experiments, abnormal astrocytes and AQP4 expression are very common characteristics of the pathology of mood disorders, which may be the main cause of glymphatic system dysfunction, but the contradictory experimental results require further integration and analysis.

Headache

Headache, especially migraine, is closely related to mood disorders. The prevalence rate of migraine in clinical samples of patients with BD is 34.8% (Fornaro and Stubbs, 2015). At
migraine symptoms caused by glymphatic system dysfunction. The finding may supplement the pathophysiological mechanism of the relationship between the glymphatic system and migraine was proven. This study further showed that sleep disorders cause glymphatic system disorders, resulting in the accumulation of CGRP in the brain and subsequently the symptoms of migraine.

### IMAGING STUDY

One of the main reasons for the doubt or contradictions in related research is the lack of mature imaging technology for glymphatic system. In recent years, a large number of studies have tried to use visualization technology to observe and describe the glymphatic system. The initial study used two-photon imaging observations, including fluorescent tracers and laser scanning microscopes, to discover the relationship between the glymphatic system and sleep (Xie et al., 2013) and found that alcoholism may lead to glymphatic system dysfunction (Liu Q. et al., 2020). Although optical imaging technology, such as two-photon microscopy, occupies a dominant position in the field of two-photon microscopy, it is gradually being replaced by MRI because of its strong invasiveness.

MRI methods have been proven to be useful for the evaluation of glymphatic system in many experiments (Jiang, 2019; Taoka and Naganawa, 2020a,b). At present, the most commonly used MRI contrast agent is gadolinium-based contrast agent (GBCA). Iliiff et al. (2013a) performed an intrathecal injection of the paramagnetic contrast agent GBCA and used dynamic contrast-enhanced MRI to display glymphatic function in the brains of living rats. This method characterizes the dynamic and spatial distribution of the glymphatic system in the whole brain. Because MRI has the least interference with the living body, similar methods have been used to study the glymphatic system in human subjects. A glymphatic system in humans similar to that found in the brains of rodents has been identified (Eide et al., 2018; Ringstad et al., 2018; Watts et al., 2019). Ringstad et al. (2017) used intrathecal GBCA as a CSF/ISF tracer for MRI and concluded that the glymphatic clearance rate was decreased in patients with inNPH. van de Haar et al. (2016) also used GBCA injection to confirm that the global blood-brain barrier leakage in patients with early AD was related to the decline of cognitive ability, reflecting the role of glymphatic system dysfunction in the pathological development of AD.

### TABLE 1 | Studies of astrocytes in postmortem tissues.

| References                  | Pathological type | Brain regions of concern                                      | Result                                      |
|-----------------------------|-------------------|----------------------------------------------------------------|---------------------------------------------|
| Torres-Piñatas et al., 2016 | Depression        | Mediodorsal thalamus and caudate nucleus                      | Downregulation of the GFAP mRNA            |
| Gittins and Harrison, 2011  | Mood disorder     | Anterior cingulate cortex                                     | Decreased GFAP protein levels               |
| Cobb et al., 2016           | MDD               | Left hippocampus                                              | Decreased number of GFAP-positive astrocytes|
| Altschuler et al., 2010      | MDD               | Amygdala                                                     | Decreased number of GFAP-positive astrocytes|
| Bernard et al., 2011         | MDD               | Locus coeruleus                                              | Downregulated GFAP expression              |
| Barley et al., 2009          | MDD               | Basal ganglia                                                 | Uregulated GFAP expression                 |
| Williams et al., 2013        | Mood disorder     | Cingulate cortex                                             | Unchanged density of astrocytes            |
| Feresten et al., 2013        | BD                | BA9                                                          | Increased GFAP expression                   |
| Webster et al., 2005         | BD                | Cingulate cortex                                             | Decreased level of the GFAP mRNA           |
| Johnston-Wilson et al., 2000 | BD                | BA10                                                         | Decreased number of GFAP-positive astrocytes|
| Toro et al., 2006            | BD                | BA11/47                                                      | Decreased number of GFAP-positive astrocytes|
| Fatemi et al., 2004          | Mood disorder     | Cerebellum                                                   | Decreased GFAP protein levels              |
| Hercher et al., 2014         | BD                | Frontal cortex                                               | Unchanged density of astrocytes            |
| Pantazopoulos et al., 2010   | BD                | Amygdala and entorhinal cortex                                | Unchanged density of astrocytes            |

GFAP, glial fibrillary acidic protein; MDD, major depressive disorder; BD, bipolar disorder; BA9, Brodmann Area 9; BA10, Brodmann Area 10; BA11/47, Brodmann Area 11/47.
Conducted animal experiments with intravenous injection of GBCA and found that the distribution of GBCA in brain tissue was affected by circadian rhythm and anesthesia. Currently, a variety of MRI methods have been developed to evaluate CSF movement, such as MRI tracer studies using the stable isotope $^{17}$O (Igarashi et al., 2014), multiple echo time (multi-TE) arterial spin labeling (ASL) MRI techniques (Ohene et al., 2019), and DTI-Alps methods to evaluate the movement of water molecules in the space around blood vessels by measuring the diffusion coefficient (Taoka et al., 2017). Abnormal glymphatic system function has been observed in the pathological processes of idiopathic normal pressure hydrocephalus (Ringstad et al., 2017; Eide and Ringstad, 2019), stroke (Gaberel et al., 2014), type 2 diabetes (Jiang et al., 2017; Yang et al., 2020), and juvenile myoclonic epilepsy (Lee et al., 2021). Different research groups have used MRI data for mathematical modeling to better understand the dynamics of glymphatic system flow (Kaur et al., 2020).

However, to date, no imaging technique has been established to directly and clearly depict the glymphatic system and neurofluid dynamics (especially in human experiments). Intrathecal injection of large doses of GBCA may cause severe gadolinium encephalopathy, potentially resulting in nausea, dyspnea, spasmodic pain of the lower extremities, and even death (Samardzic and Thamburaj, 2015; Reeves et al., 2017; Provenzano et al., 2019). Future neuroscience research is needed to develop increasingly precise measurement techniques for glymphatic system function with less of an effect on normal physiological homeostasis and to improve relevant theories by obtaining quantitative data on various components of the glymphatic system as a method to obtain a deeper understanding of the relationship between the glymphatic system and various diseases.

**CONCLUSION AND PROSPECTS FOR THE FUTURE**

Although glymphatic system dysfunction have been observed in individuals with a variety of pathological conditions, including central nervous system diseases and mood disorders, researchers have not clearly determined whether glymphatic system damage is the cause or result of these diseases (or both) (Mestre et al., 2017). The relationship between glymphatic dysfunction and diseases, as well as the specific underlying pathophysiological processes, are not understood. In recent years, the concept of “CNS interstitial fluidopathy” has been put forward by researchers, which refers to a variety of diseases characterized by glymphatic system dysfunction or other mechanisms related to interstitial fluid dynamics (Taoka and Naganawa, 2021). The in-depth study of the relationship between these diseases and glymphatic system will not only deepen our understanding of the glymphatic system and the pathogenic mechanism of related diseases, but also promote the development of clinical treatment and prevention strategies.

In addition, some doubts persist about the glymphatic system hypothesis. First, the model based on the Navier–Stokes equation and convection-diffusion equation related to fluid motion shows that the flow resistance of water molecules through the terminal AQP4 channel on astrocytes is too large to cause a large amount of fluid flow in the interstitial space, and thus researchers have questioned the regulatory role of AQP4 in CSF flow (Jin et al., 2016). Second, regarding the driving force of the glymphatic system, Asgari et al. (2016) used mathematical modeling to prove that the arterial pulse in the tissue is too small to be the driving force for large amounts of fluid flow, while the effects of other influencing factors, such as respiration and body position, must be further clarified. Third, other processes to remove waste in the brain might exist, such as transport across the blood brain barrier (Abbott et al., 2010), degradation mediated by enzymes expressed by astrocytes (Yin et al., 2006), and macrophage uptake (Hawkes and McLaurin, 2009), but the relationship between the glymphatic system and these pathways is still unknown. Therefore, future research should focus on elucidating the driving force of the glymphatic system and whether other possible driving factors exist, as well as their effects on the glymphatic system.

Sleep and endocrine factors play important roles in regulating the brain and peripheral organs. Sleep deprivation will increase the peripheral distribution of inflammatory markers in humans and rodents (Millington et al., 2010; Hurtado-Alvarado et al., 2013; Irwin et al., 2016), while pathological signals from the brain promote systemic inflammation through the VEGF-C/VEGFR3 signaling pathway (Esposito et al., 2019). The characteristics of brain aging include disorders of mitochondrial energy metabolism, activation of inflammatory bodies, oxidative damage, autophagy defects, inflammation, and impaired waste disposal mechanisms (Franceschi et al., 2018; Mészáros et al., 2020). The normal physiological process of aging might also cause glymphatic system dysfunction through sleep disorders and endocrine abnormalities. The change in the normal sleep pattern is directly related to aging (Mander et al., 2017), and this change may inhibit the clearance function of the glymphatic system by reducing NREM sleep (Hablitz et al., 2019) and increasing AQP4 mislocalization (Kress et al., 2014). The normal aging process also leads to chronic changes in the phenotype of microglia similar to the proinflammatory response (Tay et al., 2017), and activated microglia are part of the process inducing the formation of A1-like reactive astrocytes (Clarke et al., 2018), coupled with the cellular senescence characteristics of astrocytes themselves, such as increased levels of GFAP (Cotrina and Nedergaard, 2002; Finch, 2003) and vimentin filaments (Clarke et al., 2018); increased expression of cytokines such as tumor necrosis factor $\alpha$ (TNF- $\alpha$), IL-1b and IL-6 (Campuzano et al., 2009); and increased accumulation of proteotoxic aggregates (Clarke et al., 2018). Lipids may also be secreted by astrocytes in an autocrine fashion, into PVs, potentially to signal to other astrocytes, ultimately effecting ion fluxes and downstream phosphorylation pathways that themselves contribute to modulating the release or uptake of many other signaling agents (Rangroo Thrane et al., 2013). Therefore, abnormal astrocytes may affect the neural networks macroscopically. These changes may affect the normal operation of the macroscopic waste removal system in the brain through the endocrine pathway. Since sleep disorders and endocrine disorders caused by aging involve both brain and peripheral regulation and glymphatic system function, we infer that the
glymphatic system plays a certain role in regulating the brain and peripheral organs. However, the role of the glymphatic system requires further study in the future.

AUTHOR CONTRIBUTIONS

BL made the conception and design of the work, and revised the manuscript draft. DZ and XL reviewed the literature and wrote the manuscript draft. All authors contributed to the article and approved the submitted version.

REFERENCES

Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25. doi: 10.1016/j.nbd.2009.07.030
Ahmed, R. M., Newcombe, R. E., Piper, A. J., Lewis, S. J., Yee, B. J., Kiernan, M. C., et al. (2016). Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med. Rev. 26, 33–42. doi: 10.1016/j.smrv.2015.05.007
Albrecht, U. (2013). Circadian clocks and mood-related behaviors. Handb. Exp. Pharmacol. 217, 227–239. doi: 10.1007/978-3-642-25950-0_9
Altschuler, L. L., Abulseed, O. A., Foland-Ross, L., Bartzokis, G., Chang, S., Mintz, J., et al. (2010). Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord. 12, 541–549. doi: 10.1111/j.1399-5618.2010.00838.x
Antonacci, F., Nappi, G., Galli, F., Manzioni, G. C., Calabresi, P., and Costa, A. (2011). Migraine and psychiatric comorbidity: a review of clinical findings. J. Headache Pain 12, 115–125. doi: 10.1007/s10194-010-0282-4
Arent, C. O., Valvassori, S. S., Steckert, A. V., Resende, W. R., Dal-Pont, G. C., Lopes-Borges, J., et al. (2015). The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxic sleep deprivation model of mania. J. Psychiatr. Res. 65, 71–79. doi: 10.1016/j.jpsychires.2015.04.011
Armstrong, R. A. (2009). The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol. 47, 289–299.
Asgari, M., de Zélicourt, D., and Kurtcuoglu, V. (2016). Glymphatic solute transport does not require bulk flow. Sci. Rep. 6:38635. doi: 10.1038/srep38635
Barber, A., and Dashtipour, K. (2012).Sleep disturbances in Parkinson's disease with and without cognitive impairment. J. Neurol. Sci. 317, 115–125. doi: 10.1016/j.jns.2011.04.028-2
Beral, S., Klis, A., and Raisman-Gonogofsky, C. (2015). Alpha-synuclein as a mediator in the interplay between aging and Parkinson’s disease. Biomolecules 5, 2675–2700. doi: 10.3390/biom5042675
Bolay, H., Reuter, U., Dunn, A. K., Huang, Z., Boas, D. A., and Moskowitz, M. A. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8, 136–142. doi: 10.1038/nmm0202-136
Bolte, A. C., and Lukens, J. R. (2021). Neuroimmune cleanup crew action in brain injury. Trends Immunol. 42, 480–494. doi: 10.1016/j.ti.2021.04.003
Bohnen, N. I., and Hu, M. T. M. (2019). Sleep disturbance as potential risk and progression factor for Parkinson’s disease. J. Parkinsons Dis. 9, 603–614. doi: 10.3233/jpd-191627
Bolano, D., and Zuccato, C. (2019). Migraine and psychiatric comorbidity: a review of clinical findings. J. Affect. Disord. 10.3233/jpd-191627
Brady, A. J., Webb-Mitchell, R., Hasz, A., Slater, N., Middleton, B., Gallagher, P., et al. (2017). Sleep and circadian rhythm disturbance in bipolar disorder. Psychol. Med. 47, 1678–1689. doi: 10.1017/s0033291717000186
Cai, X., Qiao, J., Kulkarni, P., Harding, I. C., Ebong, E., and Ferris, C. F. (2020). Imaging the effect of the circadian light-dark cycle on the glymphatic system in awake rats. Proc. Natl. Acad. Sci. U.S.A. 117, 668–676. doi: 10.1073/pnas.1914017117
Campuzano, O., Castillo-Ruiz, M. M., Acarin, L., Castellano, B., and Gonzalez, B. (2009). Increased levels of proinflammatory cytokines in the aged rat brain attenuate injury-induced cytokine response after excitotoxic damage. J. Neurosci. Res. 87, 2484–2497. doi: 10.1002/jnr.22074
Capone, P. M., Bertelson, J. A., and Aitai, B. (2020). Neuroimaging of normal pressure hydrocephalus and hydrocephalus. Neuro. Clin. 38, 171–183. doi: 10.1016/j.ncl.2019.09.003
Che, Y. B., Yan, D. Y., Zhou, Y. R., Jiang, Y., Melcher, K., et al. (2017). Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 38, 1205–1235. doi: 10.1038/aps.2017.28
Chi, P. L., Chen, H. L., Lu, C. H., Chen, Y. S., Chou, K. H., Hsu, T. W., et al. (2016). Repetitive mild traumatic brain injury alters glymphatic clearance rates in limbic structures of adolescent female rats. Sci. Rep. 6:25. doi: 10.1038/srep19598
Christensen, J., Wright, D. K., Yamakawa, G. B., Shultz, S. R., and Mychasiuk, R. (2020). Repetitive mild traumatic brain injury alters glymphatic clearance rates in limbic structures of adolescent female rats. Sci. Rep. 10.1038/s41598-020-63022-7
Clarke, L. E., Liddelow, S. A., Chakraborty, C., Munch, A. E., Heiman, M., and Barres, B. A. (2018). Normal aging induces A1-like astrocyte activity. Proc. Natl. Acad. Sci. U.S.A. 115, E1896–E1905. doi: 10.1073/pnas.180016511
Clinchot, D. M., Bogner, J., Mysiw, W. J., Fugate, L., and Corrigan, J. (1998). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. J. Neurosci. Res. 42, 33–42. doi: 10.1002/(sici)1097-4176(199804)42:1<33::aid-jnr1>3.0.co;2-g
Cohen, J. A., O’Neill, K., Milner, J., Mahajan, G. J., Lawrence, T. J., May, W. L., et al. (2016). Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience 316, 209–220. doi: 10.1016/j.neuroscience.2015.12.044
Colin, J., Orr, N., Lettieri, C. J., Carter, K., and Holley, A. B. (2012). Sleep disturbances among soldiers with combat-related traumatic brain injury. Chest 142, 622–630. doi: 10.1378/chest.11-1603
Cotrina, M. L., and Nedergaard, M. (2002). Astrocytes in the aging brain. J. Neurosci. Res. 67, 1–10. doi: 10.1002/jnr.10121
Czech, B., Simon, M., Schmelting, B., Hiemke, C., and Fuchs, E. (2006). Astrogial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 31, 1616–1626. doi: 10.1038/sj.npp.1300982
da Rosa, M. I., Simon, C., Grande, A. J., Barichello, T., Oses, J. P., and Quevedo, J. (2016). Serum S100B in manic bipolar disorder patients: systematic review and meta-analysis. J. Affect. Disord. 206, 210–215. doi: 10.1016/j.jad.2016.07.030

FUNDING

This work was supported by the National Natural Science Foundation of China, BL (Grant No. 81871852), Shenyang Science and Technology Innovation Talents Project, BL (Grant No. RC202078), and “ChunHui” Program of Education Ministry, BL (Grant No. 2020703).
Gabbita, S. P., Scheff, S. W., Menard, R. M., Roberts, K., Fugaccia, I., and Zemlan, F. P. (2005). Cleaved-tau: a biomarker of neuronal damage after traumatic brain injury. J. Neurotrauma 22, 63–94. doi: 10.1089/neuro.2005.22.83

Gaberel, T., Gakuba, C., Goulay, R., Martinez De Lizarrondo, S., Hanouz, J. L., Emery, E., et al. (2014). Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis? Stroke 45, 3092–3096. doi: 10.1161/strokeaha.114.006617

Gallina, P., Porfiri, B., and Lolli, F. (2020). iNPH as a ‘2-hit’ intracranial hydrodynamic derangement disease. Trends Mol Med 26, 531–532. doi: 10.1016/j.molmed.2020.04.002

Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., et al. (2011). Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134(Pt 12), 3697–3707. doi: 10.1093/brain/awr300

Geuens, T., Bouhy, D., and Timmerman, V. (2016). The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867. doi: 10.1007/s00439-016-1683-5

Gittins, R. A., and Harrison, P. J. (2011). A morphometric study of glia and neurons in the anterior cingular cortex in mood disorder. J. Affect. Disord. 133, 328–332. doi: 10.1016/j.jad.2011.03.042

Giza, C. C., and Hovda, D. A. (2014). The new neurometabolic cascade of concussion. Neurosurgery 75(Suppl 4), S24–S33. doi: 10.1227/neo.0000000000000505

Gong, Y., Sun, X. L., Wu, F. F., Su, C. J., Ding, J. H., and Hu, G. (2012). Female early adult depression results in detrimental impacts on the behavioral performance and brain development in offspring. CNS Neurosci. Ther. 18, 461–470. doi: 10.1111/j.1755-5949.2012.00324.x

Goulay, R., Aron Badin, R., Flament, J., Emery, E., Hantraye, P., Vivien, D., et al. (2018). Cerebrospinal fluid leakage after posterior fossa surgery may impair brain metabolite clearance. Neurochirurgie 64, 422–424. doi: 10.1016/j.neuchi.2018.08.003

Goulay, R., Flament, J., Gauberti, M., Naveau, M., Pasquet, N., Gakuba, C., et al. (2017). Subarachnoid hemorrhage severely impairs brain parenchymal cerebrospinal fluid circulation in nonhuman primate. Stroke 48, 2301–2305. doi: 10.1161/strokeaha.117.017014

Grinberg, L. T., Rueb, U., Alho, A. T., and Heinzen, H. (2010). Brainstem pathology and non-motor symptoms in PD. J. Neurosci. 28, 891–898. doi: 10.1523/jneurosci.142109.09.08.21

Habiltz, L. M., Plá, V., Giannitsi, M., Vinitsky, H. S., Stager, F. F., Metcalfe, T., et al. (2020). Circadian control of brain glymphatic and lymphatic fluid flow. Nat. Commun. 11:4411. doi: 10.1038/s41467-020-18115-2

Habiltz, L. M., Vinitsky, H. S., Sun, Q., Stager, F. F., Sigurdsson, B., Mortensen, K. N., et al. (2019). Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci. Adv. 5:eaa55447. doi: 10.1126/sciadv.aav5447

Hakim, S., and Adams, R. D. (1965). The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J. Neuros. Sci. 2, 307–327. doi: 10.1016/0022-510x(65)90016-x

Harrison, I. F., Ismail, O., Machhada, A., Colgan, N., Obene, Y., Nahavandi, P., et al. (2020). Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain 143, 2576–2593. doi: 10.1093/brain/awaa179

Hasan-Olive, M. M., Enger, R., Hansson, H. A., Nagelhus, E. A., and Eide, P. K. (2019). Loss of perivascular aquaporin-4 in idiopathic normal pressure hydrocephalus. Glia 67, 91–100. doi: 10.1002/glia.23528

Hawkes, C. A., and McLaurin, J. (2009). Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A. 106, 1261–1266. doi: 10.1073/pnas.0805435106

Henderson, M. X., Trojanowski, J. Q., and Lee, V. M. (2019). α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Neurosci. 170:934316. doi: 10.1161/neure.2019.134316

Hercher, C., Chopra, V., and Beasley, C. L. (2014). Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. J. Psychiatry Neurosci. 39, 376–385. doi: 10.1503/jpns.130277

Hirose, M., Asano, M., Watanabe-Matsumoto, S., Yamanaka, K., Abe, Y., Yasui, M., et al. (2021). Stagnation of glymphatic interstitial fluid flow and delay in waste clearance in the SOD1-G93A mouse model of ALS. Neurosci. Res. 171, 74–82. doi: 10.1016/j.neures.2020.10.006

Hoshi, A., Tsumoda, A., Tada, M., Nishizawa, M., Uyawa, Y., and Kikati, A. (2017). Expression of Aquaporin 1 and Aquaporin 4 in the temporal neocortex of patients with Parkinson's disease. Brain Pathol. 27, 160–168. doi: 10.1111/bpa.12369

Hurtado-Alvarado, G., Pavón, L., Castillo-García, S. A., Hernández, M. E., Domínguez-Salazar, E., Velázquez-Moctezuma, J., et al. (2013). Sleep loss as a factor to induce cellular and molecular inflammatory variations. Clin. Dev. Immunol. 2013:801341. doi: 10.1155/2013/801341
Igarashi, H., Tsuji, M., Kwee, I. L., and Nakada, T. (2014). Water influx into cerebrospinal fluid is primarily controlled by aquaporin-4, not by aquaporin-1: 170 JIF/CPE MRI study in knockout mice. *Neuroreport* 25, 39–43. doi: 10.1097/ wrn.000000000000042

Ilfiff, J. J., Chen, M. J., Plogg, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Ilfiff, J. J., Lee, H., Yu, M., Feng, T., Logan, J., Niedergaard, M., et al. (2013a). Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. *J. Clin. Invest.* 123, 1299–1309. doi: 10.1172/jci67677

Ilfiff, J. J., Wang, M., Zeppenfeld, D. M., Venkataraman, A., Plogg, B. A., Liao, Y., et al. (2013b). Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. *J. Neurosci.* 33, 18190–18199. doi: 10.1523/ neursci.1592-13.2013

Ilfiff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of intermittent solutes, including amyloid β. *Sci. Transl. Med.* 4:147ra111. doi: 10.1126/scitranslmed.3003748

Imbesi, M., Yildiz, S., Dirim Arslan, A., Sharma, R., Manev, H., and Uz, T. (2009). Dopamine receptor-mediated regulation of neuronal “clock” gene expression. *Neuroscience* 158, 537–544. doi: 10.1016/j.neuroscience.2008.10.044

Inglese, M., Bomsztyk, E., Gonen, O., Mannon, L. J., Grossman, R. I., and Rusinek, H. (2005). Dilated perivascular spaces: hallmarks of mild traumatic brain injury. *AJNR Am. J. Neuroradiol.* 26, 719–724.

Irwin, M. R., Olmstead, R., and Carroll, J. E. (2016). Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. *Biol. Psychiatry* 80, 40–52. doi: 10.1016/j.biopsych.2015.05.014

Isaac, S. O., and Berridge, C. W. (2003). Wake-promoting actions of dopamine D1 and D2 receptor stimulation. *J. Pharmacol. Exp. Ther.* 307, 386–394. doi: 10.1124/jpet.103.053918

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014

Iwamoto, K., Kakiuchi, C., Bundo, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J. Neurosci.* 34, 16180–16193. doi: 10.1523/ neursci.3020-14.2014
Liu, Q., Yan, L., Huang, M., Zeng, H., Satyanarayanan, S. K., Shi, Z., et al. (2020). Experimental alcoholism primes structural and functional impairment of the glymphatic pathway. Brain Behav. Immun. 85, 106–119. doi: 10.1016/j.bbi.2019.06.029

Liu, X., Hao, J., Yao, E., Cao, J., Zheng, X., Yao, D., et al. (2020). Polysaturated fatty acid supplement alleviates depression-related cognitive dysfunction by protecting the cerebrovascular and glymphatic systems. Brain Behav. Immun. 89, 357–370. doi: 10.1016/j.bbi.2020.07.022

Lu, V. M., Kerezoudis, P., Patel, N. P., Jones, D. T., Cutsforth-Gregory, J. K., Graff-Radford, J., et al. (2020). Our efforts in understanding normal pressure hydrocephalus: learning from the 100 most cited articles by bibliometric analysis. World Neurosurg. 137, 429–434.e13. doi: 10.1016/j.wneu.2020.02.021

Lundgaard, I., Li, B., Xie, L., Kang, H., Sanggaard, S., Haswell, J. D., et al. (2015). Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism. Nat. Commun. 6:8007. doi: 10.1038/ncomms7807

Luo, C., Yao, X., Li, J., He, B., Liu, Q., Ren, H., et al. (2016). Paravascular pathways contribute to vasculitis and neuroinflammation after subarachnoid hemorrhage independently of glymphatic control. Cell Death Dis. 7:e2160. doi: 10.1038/cddis.2016.63

Lyall, L. M., Wyse, C. A., Graham, N., Ferguson, A., Lyall, D. M., Cullen, B., et al. (2018). Association of disrupted circadian rhythmicity with mood disorders, subjective wellbeing, and cognitive function: a cross-sectional study of 91,105 subjects. J. Psychiatr Res. 1007/s11064-012-0818-x

Marder, B. A., Winer, J. R., and Walker, M. P. (2017). Sleep and human aging. Lancet Psychiatry 4(12):785–797. doi: 10.1016/S2215-0366(18)30139-1

Mestre, H., Habimana-Griffin, L., Achilefu, S., Alitalo, K., et al. (2015). Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science 349, 1381–1383. doi: 10.1126/science.1254089

Mullington, J. M., Simpson, N. S., Meier-Ewert, H. K., and Haack, M. (2010). Sleep metabolism. Nat. Commun. 1:6807. doi: 10.1038/ncomms7807

Mészáros, Á., Molnár, K., Nógrádi, B., Hernádi, Z., Nyúl-Tóth, Á., Wilhelm, I., et al. (2018). Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism. Nat. Commun. 6:8007. doi: 10.1038/ncomms7807

Murdoch, L. A., Yang, Q., Parsons, M. W., Levi, C. R., Beard, D. J., Spratt, N. J., et al. (2014). Cerebrospinal fluid is drained primarily via the spinal canal and olfactory route in young and aged spontaneously hypertensive rats. Fluids Barriers CNS 11:12. doi: 10.1186/2045-8118-11-12

Nagelhus, E. A., and Ottersen, O. P. (2013). Physiological roles of aquaporin-4 in brain. Physiol. Rev. 93, 1543–1562. doi: 10.1152/physrev.00011.2013

Neumann, M., Sampaith, D. M., Kwong, L. K., Truax, A. C., Micsenyi, C., Chou, T. C., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133. doi: 10.1126/science.1134108

Ng, A. S., Rademakers, R., and Miller, B. L. (2015). Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann. N. Y. Acad. Sci. 1338, 71–93. doi: 10.1111/nyas.12638

Nicaise, C., Soyfoo, M. S., Ausehe, M., De Decker, R., Bataillé, D., Delporte, C., et al. (2009). Aquaporin-4 overexpression in rat ALS model. Anat. Rec. (Hoboken) 292, 207–213. doi: 10.1002/ar.20838

Nielsen, S., Nagelhus, E. A., Amiry-Moghaddam, M., Bourque, C., Agre, P., and Ottersen, O. P. (1997). Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci. 17, 171–180. doi: 10.1523/jneurosci.17-01-00171.1997

Nilsson, C., Lindvall-Axelson, M., and Owman, C. (1992). Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Brain Res. Rev. 17, 109–138. doi: 10.1016/1567-9901(92)90011-a

O'Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S., and Nedergaard, M. (2012). Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 37, 2496–2512. doi: 10.1007/s11064-012-0818-x

Ohene, Y., Harrison, I. F., Nahavandi, P., Ismail, O., Bird, E. V., Ottersen, O. P., et al. (2019). Non-invasive MRI of brain clearance pathways using multiple echo time arterial spin labelling: an aquaporin-4 study. Neuroimage 188, 515–523. doi: 10.1016/j.neuroimage.2018.12.026

Okamoto, Y., Yamamoto, T., Kalaria, R. N., Senzaki, H., Maki, T., Hase, Y., et al. (2012). Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol. 123, 381–394. doi: 10.1007/s00401-011-0925-9

Omos, S., and Yu, J. (2016). Treatment of sleep disorders in dementia. Curr. Treat Options Neurol. 18:40. doi: 10.1007/s11940-016-0424-3

Oresković, D., and Klarica, M. (2010). The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res. Rev. 64, 241–262. doi: 10.1016/j.brainresrev.2010.04.006

Ouettel, M. C., Beauvile-Bonneau, S., and Morin, C. M. (2006). Insomnia in patients with traumatic brain injury: frequency, characteristics, and risk factors. J. Head Trauma Rehabil. 21, 199–212. doi: 10.1097/01.HTR.00001999-000000001

Pantazopoulos, H., Woo, T. U., Lim, M. P., Lange, N., and Berretta, S. (2010). Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 67, 155–166. doi: 10.1001/archgenpsychiatry.2009.196

Park, H., Lee, K. H., and Lee, K. (2018). Chronotype and suicide: the mediating effect of depressive symptoms. Psychiatry Res. 269, 316–320. doi: 10.1016/j.psychres.2018.08.046

Patel, T. K., Habimana-Griffin, L., Gao, X., Xu, B., Achilefu, S., Alitalo, K., et al. (2019). Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol. Neurodegener. 14:11. doi: 10.1186/s13204-019-0312-x

Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, H., et al. (2016). Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. Neurobiol. Dis. 93, 219–225. doi: 10.1016/j.nbd.2016.05.015

Plog, B. A., Dashnaw, M. L., Hitomi, E., Peng, W., Liao, Y., Lou, N., et al. (2015). Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci. 35, 518–526. doi: 10.1523/jneurosci.3742-14.2015

Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., and Patel, B. K. (2019). Motor mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 12:25. doi: 10.3389/fnmol.2019.00025

Provenzano, D. A., Pellis, Z., and DeRiggi, L. (2019). Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report
Shokri-Kojori, E., Wang, G. J., Wiers, C. E., Demiral, S. B., Guo, M., Kim, S. W., et al. (2018). β-Amyloid accumulation in the human brain after one night of sleep deprivation. *Proc. Natl. Acad. Sci. U.S.A.* 115, 4483–4488. doi: 10.1073/pnas.1721694115

Simon, M. J., Wang, M. X., Murchison, C. F., Roese, N. E., Boesplug, E. L., Woltjer, R. L., et al. (2018). Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. *Sci. Rep.* 8:12389. doi: 10.1038/s41598-018-30779-x

Singh, N. N., and Sahota, P. (2013). Sleep-related headache and its management. *Curr. Treat. Options Neurol.* 15, 704–722. doi: 10.1007/s11940-013-0258-1

Siow, T. Y., Toh, C. H., Hsu, J. L., Liu, G. H., Lee, S. H., Chen, N. H., et al. (2021). Association of sleep, neuropsychological performance, and gray matter volume with glympatic function in community-dwelling older adults. *Neurology* 98, e829–e838. doi: 10.1212/WNL.0000000000013215

Sjöholm, L. K., Backlund, L., Cheteh, E. H., Ek, J. R., Friesen, L., Schalling, M., et al. (2010). CRY2 is associated with rapid cycling in bipolar disorder patients. *PLoS One* 5:e12632. doi: 10.1371/journal.pone.0012632

Stavisky, K., Neargarder, S., Bogdanova, Y., McNamara, P., and Cronin-Golomb, A. (2012). The impact of sleep quality on cognitive functioning in Parkinson’s disease. *J. Int. Neuropsychol. Soc.* 18, 108–117. doi: 10.1017/s1355617711001482

Sundaram, S., Hughes, R. L., Peterson, E., Müller-Oehring, E. M., Bronté-Stewart, H., Poston, K. L., et al. (2019). Establishing a framework for neuropathological correlates and glympatic system functioning in Parkinson’s disease. *Neurosci. Biobehav. Rev.* 103, 305–315. doi: 10.1016/j.neubiorev.2019.03.016

Tabaton, M., and Piccini, A. (2005). Role of water-soluble amyloid-beta in the pathology of Alzheimer’s disease. *Int. J. Exp. Pathol.* 86, 139–145. doi: 10.1111/j.0959-9673.2005.00428.x

Taoka, T., Jost, G., Brenzel, T., Naganawa, S., and Pietsch, H. (2018). Impact of the glympatic system on the kinetic and distribution of gadodiamide in the rat brain: observations by dynamic MRI and effect of circadian rhythm on tissue gadolinium concentrations. *Invest. Radiol.* 53, 529–534. doi: 10.1097/rlr.0000000000000473

Taoka, T., Masutani, Y., Kawai, H., Nakane, T., Matsuoka, K., Yasuno, F., et al. (2017). Evaluation of glympatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. *Ipn. J. Radiol.* 35, 172–178. doi: 10.1107/s11604-017-0617-x

Taoka, T., and Naganawa, S. (2020a). Glympatic imaging using MRI. *J. Magn. Reson. Imaging* 51, 11–24. doi: 10.1002/jmri.26892

Taoka, T., and Naganawa, S. (2020b). Neurofluid dynamics and the glympatic system: a neuroimaging perspective. *Korean J. Radiol.* 21, 1199–1209. doi: 10.3348/kjr.2020.00442

Taoka, T., and Naganawa, S. (2021). Evaluation of glympatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. *Ipn. J. Radiol.* 35, 172–178. doi: 10.1107/s11604-017-0617-x

Taylor, J., Hardy, J., and Fischbeck, K. H. (2002). Toxic proteins in neurodegenerative disease. *Science* 296, 1991–1995. doi: 10.1126/science.106722

Toro, C. T., Hallak, J. E., Dunham, J. S., and Deakin, J. F. (2006). Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides. *Mol. Psychiatry* 21, 509–515. doi: 10.1038/mp.2015.65

Trillo-Contreras, J. L., Toledo-Aral, J. J., Echevarria, M., and Villadiego, J. (2019). AQPI and AQP4 contribution to cerebrospinal fluid homeostasis. *Cells* 8:197. doi: 10.3390/cells8020197
van de Haar, H. J., Burgmans, S., Jansen, J. F., van Osch, M. J., van Buchem, M. A., Muller, M., et al. (2016). Blood-brain barrier leakage in patients with early Alzheimer disease. *Radiology* 281, 527–535. doi: 10.1148/radiol.2016152244

Verkhratsky, A., Nedergaard, M., and Hertz, L. (2015). Why are astrocytes important? *Neurochem. Res.* 40, 389–401. doi: 10.1007/s11064-014-1403-2

Verma, A., Anand, V., and Verma, N. P. (2007). Sleep disorders in chronic traumatic brain injury. *J. Clin. Sleep Med.* 3, 357–362. doi: 10.5664/jcsm.26856

Wang, J., Huang, Q., Li, N., Tan, G., Chen, L., and Zhou, J. (2013). Triggers of migraine and tension-type headache in China: a clinic-based survey. *Eur. J. Neurol.* 20, 689–696. doi: 10.1111/ene.12039

Zou, W., Pu, T., Feng, W., Lu, M., Zheng, Y., Du, R., et al. (2019). Blocking aquaporin-4 mediates astrocyte response to β-amyloid. *Mol. Cell. Neurosci.* 49, 406–414. doi: 10.1016/j.mcn.2012.02.002

Yokota, H., Vijayasarthi, A., Cekic, M., Hirata, Y., Linetksy, M., Ho, M., et al. (2019). Diagnostic performance of glialytic system evaluation using diffusion tensor imaging in idiopathic normal pressure hydrocephalus and mimickers. *Curr. Gerontol. Geriatr. Res.* 2019;5675014. doi: 10.1155/2019/5675014

Yuan, H., Lauritzen, C. G., Kaiser, E. A., and Silberstein, S. D. (2017). CGRP monoclonal antibodies for migraine: rationale and progress. *Biodrugs* 31, 487–501. doi: 10.3389/s40259-017-0250-5

Zebesko, J. C., Nguyen, T. V., Yang, T., Frye, J. B., Hussain, O., Hayes, M., et al. (2018). Glial scars are permeable to the neurotoxic environment of chronic stroke infarcts. *Neurol. Dis.* 112, 63–78. doi: 10.1016/j.nbd.2018.01.007

Zeppenfeld, D. M., Simon, M., Haswell, J. D., D’Albreo, D., Murchison, C., Quinn, J. F., et al. (2017). Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. *JAMA Neurol.* 74, 91–99. doi: 10.1001/jamaneurol.2016.4370

Zhang, J., Yang, B., Sun, H., Zhou, Y., Liu, M., Ding, J., et al. (2016). Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson’s disease. *Neurosci. Lett.* 614, 7–15. doi: 10.1016/j.neulet.2015.12.057

Zhang, Z., and Khatami, R. (2014). Predominant endothelial vasomotor activity during human sleep: a near-infrared spectroscopy study. *Eur. J. Neurosci.* 40, 3396–3404. doi: 10.1111/ejn.12702

Zou, W., Xu, F., Chen, Y., Wu, Q., Yuan, C., Gao, J., Xiao, M., Gu, M., et al. (2012). Aquaporin-4 mediates astrocyte response to β-amyloid. *Mol. Neurodegener.* 3396–3404. doi: 10.1111/ejn.12702

Zou, W., Pu, T., Feng, W., Lu, M., Zheng, Y., Du, R., et al. (2019). Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. *Transl. Neurodegener.* 8:7. doi: 10.1186/s40035-019-0147-y

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.